DelveInsight’s, “Chondrosarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Chondrosarcoma pipeline landscape. It covers the Chondrosarcoma pipeline drug profiles, including Chondrosarcoma clinical trials and nonclinical stage products. It also covers the Chondrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Chondrosarcoma emerging drugs, the Chondrosarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Chondrosarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Chondrosarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Chondrosarcoma clinical trials studies, Chondrosarcoma NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Chondrosarcoma Pipeline Report
- Over 8+ Chondrosarcoma Companies are evaluating 8+ Chondrosarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Chondrosarcoma market would significantly increase market revenue.
- The leading Chondrosarcoma Companies includes Inhibrx, Inc., PharmaMar, Agios Pharmaceuticals, Iovance Biotherapeutics, Forma Therapeutics, Eli Lilly and Company, IGM Biosciences, Inc., AnHeart Therapeutics, Roche, Salarius Pharmaceuticals, and others.
- Promising Chondrosarcoma Pipeline Therapies includes Pazopanib, IPI-926, Trabectedin, Perifosine, Loperamide, Allopurinol, Antiemetics, Enasidenib, FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin, Dasatinib, and others.
- The Chondrosarcoma companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The Chondrosarcoma therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.
To explore more information on the latest breakthroughs in the Chondrosarcoma Pipeline treatment landscape of the report, click here @ Chondrosarcoma Pipeline Outlook
Chondrosarcoma Overview
Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20 percent of all primary malignant tumors of the bone and usually arise in the pelvis or long bones. Primary or conventional chondrosarcoma arises in preexisting normal bone and is distinguished from the rarer secondary tumors, which occur within a preexisting enchondroma or osteochondroma. The majority of chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. As with many cancers, the cause of chondrosarcoma is not clear. However, people with certain medical conditions have an increased risk for developing chondrosarcoma.
Recent Developmental Activities in the Chondrosarcoma Treatment Landscape
- In January 2022, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The drug is currently being evaluated in Phasr II stage of development.
- In July 2018, Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild type enzyme.
For further information, refer to the detailed Chondrosarcoma Unmet Needs, Chondrosarcoma Market Drivers, and Chondrosarcoma Market Barriers, click here for Chondrosarcoma Ongoing Clinical Trial Analysis
Chondrosarcoma Emerging Drugs Profile
- INBRX-109: Inhibrx
INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2022, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The drug is currently being evaluated in Phasr II stage of development.
- AG120: Agios Pharmaceuticals
Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild type enzyme. It is considered to be a slow-binder of the wild type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute its selectivity. Ivosidenib is a first in class isocitrate dehydrogenase-1 (IDH1) approved for use by the FDA in acute myeloid leukemia (AML) in July 2018. Ivosidenib is now available in the United States under the trade name Tibsovo marketed by Agios Pharmaceuticals, Inc. A Phase II study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Chondrosarcoma Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
Request a sample and discover the recent advances in Chondrosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Chondrosarcoma Treatment Landscape
Scope of the Chondrosarcoma Pipeline Report
- Coverage- Global
- Chondrosarcoma Companies- Inhibrx, Inc., PharmaMar, Agios Pharmaceuticals, Iovance Biotherapeutics, Forma Therapeutics, Eli Lilly and Company, IGM Biosciences, Inc., AnHeart Therapeutics, Roche, Salarius Pharmaceuticals, and others.
- Chondrosarcoma Pipeline Therapies- Pazopanib, IPI-926, Trabectedin, Perifosine, Loperamide, Allopurinol, Antiemetics, Enasidenib, FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin, Dasatinib, and others.
- Chondrosarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Chondrosarcoma Market Drivers and Chondrosarcoma Market Barriers, click here @ Chondrosarcoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Chondrosarcoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- INBRX-109: Inhibrx
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- LY3410738: Eli Lilly and Company/ Loxo Oncology
- Drug profiles in the detailed report…..
- Inactive Products
- Chondrosarcoma Key Companies
- Chondrosarcoma Key Products
- Chondrosarcoma- Unmet Needs
- Chondrosarcoma- Market Drivers and Barriers
- Chondrosarcoma- Future Perspectives and Conclusion
- Chondrosarcoma Analyst Views
- Chondrosarcoma Key Companies
- Appendix
Got Queries? Find out the related information on Chondrosarcoma Mergers and acquisitions, Chondrosarcoma Licensing Activities @ Chondrosarcoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
